Tubulointerstitial Nephritis (TIN)

1. Clinical Overview

Summary

Tubulointerstitial Nephritis (TIN), also known as Acute Interstitial Nephritis (AIN), is a common and increasingly recognized cause of Acute Kidney Injury (AKI) resulting from inflammation of the renal tubules and the interstitium—the space between tubules—typically sparing the glomeruli. It is predominantly an immunologic hypersensitivity reaction (Type IV delayed-type hypersensitivity), most commonly triggered by medications. Early recognition and withdrawal of the offending agent are critical to prevent permanent renal scarring and progression to chronic kidney disease. [1,2]

TIN accounts for 15-27% of all cases of AKI in hospitalized patients and up to 10-15% of cases requiring renal biopsy for unexplained AKI. The condition has evolved considerably over the past two decades, with proton pump inhibitors (PPIs) now rivaling traditional culprits like antibiotics and NSAIDs as leading causes. [3]

Key Facts

• The Culprits: Medications account for 70-75% of cases. The "Big 5" drug classes are:

  1. Antibiotics (β-lactams: Penicillins, Cephalosporins; Fluoroquinolones: Ciprofloxacin; Rifampicin).
  2. NSAIDs (Ibuprofen, Naproxen, COX-2 inhibitors—unique pattern with nephrotic-range proteinuria).
  3. PPIs (Omeprazole, Lansoprazole, Esomeprazole—increasingly common, insidious onset).
  4. Diuretics (Furosemide, Thiazides).
  5. Allopurinol (dose-related, often with systemic hypersensitivity).

• The "Classic Triad": Fever + Rash + Eosinophilia. However, this full triad is only seen in 10-15% of patients. The absence of this triad does NOT exclude TIN—most cases present with non-specific AKI. [4]

• Sterile Pyuria: A key diagnostic clue. The urine dipstick shows Leukocytes (+++) but urine culture is negative (because the inflammation is immunologic/allergic, not bacterial).

• White Cell Casts: Pathognomonic finding on urine microscopy, distinguishing TIN from glomerulonephritis (which shows red cell casts).

Clinical Pearls

PPI Nephritis: Proton Pump Inhibitors are now a leading cause of AIN, especially in the elderly. The onset is typically insidious (weeks to months after initiation), unlike antibiotics (typically 7-10 days). It is often asymptomatic AKI discovered on routine laboratory testing, without fever, rash, or eosinophilia. [5,6]

NSAID Difference: NSAID-induced TIN often presents with significant proteinuria (nephrotic range, > 3.5 g/day) because NSAIDs can simultaneously cause a Minimal Change Disease-like glomerular lesion alongside the interstitial nephritis—a unique dual pathology. [7]

Urine Eosinophils: Historically taught as a diagnostic test (Hansel stain or Wright stain). Modern systematic reviews show it has poor sensitivity (30-40%) and specificity (60-70%). Do NOT rely on this test alone; its absence does not exclude TIN. [8]

Timing Matters: The latency period varies widely by drug. Antibiotics typically cause AIN within 7-14 days, NSAIDs after weeks to months, and PPIs can cause AIN even after years of use. Re-exposure can trigger AIN within 24-48 hours (anamnestic response). [9]

---

2. Epidemiology

Prevalence and Incidence

Tubulointerstitial nephritis is a significant contributor to acute kidney injury across diverse clinical settings:

Temporal Trends: The epidemiology of TIN has shifted dramatically:

• 1980s-1990s: β-lactam antibiotics (especially methicillin, now rare) were the dominant cause.
• 2000s-2010s: NSAIDs became increasingly common.
• 2010s-Present: PPIs have emerged as a leading cause, reflecting widespread PPI use (10-15% of adults in Western countries take PPIs regularly). [5,6]

Demographics

Risk Factors

Patient-Related Factors:

• Advanced age (> 65 years): Reduced renal reserve, polypharmacy [13]
• Pre-existing CKD: Baseline eGFR less than 60 ml/min/1.73m² [15]
• Hypoalbuminemia: Altered drug protein binding [16]
• Immune dysregulation: HIV infection, autoimmune disease
• Genetic predisposition: HLA-DRB1*0102 associated with NSAID-induced AIN [17]

Drug-Related Factors:

• High-dose or prolonged therapy
• Combination nephrotoxic agents (e.g., NSAID + diuretic + ACE inhibitor—"triple whammy")
• Re-exposure to previous culprit drug (accelerated reaction)

Environmental Factors:

• Volume depletion (reduces renal perfusion, concentrates drugs)
• Concomitant infection (may act as immune trigger)

Geographic Variations

• Developed countries: PPI and NSAID use predominate; antibiotic-induced AIN less common with declining use of methicillin and increasing use of less nephrotoxic agents.
• Developing countries: Infectious causes (tuberculosis, leptospirosis) and traditional medicine-associated TIN remain significant.

---

3. Aetiology & Pathophysiology

Aetiology

Drug-Induced TIN (70-75% of cases)

Antibiotics (30-40% of drug-induced cases):

• β-lactams: Penicillins (methicillin historically, now ampicillin, piperacillin), Cephalosporins (cephalexin, ceftriaxone)
• Fluoroquinolones: Ciprofloxacin, levofloxacin
• Sulfonamides: Trimethoprim-sulfamethoxazole (co-trimoxazole)
• Rifampicin: Often with systemic hypersensitivity (DRESS syndrome)
• Latency: Typically 7-14 days (median 10 days) [18]

NSAIDs (20-30% of drug-induced cases):

• Both non-selective COX inhibitors (ibuprofen, naproxen, diclofenac) and COX-2 selective inhibitors (celecoxib)
• Unique dual pathology: Interstitial nephritis + Minimal Change Disease (nephrotic syndrome)
• Latency: Weeks to months (median 2-6 months) [7]

Proton Pump Inhibitors (20-30% of drug-induced cases, increasing):

• Omeprazole > Lansoprazole > Pantoprazole, Esomeprazole, Rabeprazole
• Insidious onset; often asymptomatic
• Latency: Highly variable (weeks to years; median 3-6 months) [5,6]
• Risk factors: Age > 60, prolonged use (> 3 months), higher doses

Other Common Drugs:

• Diuretics: Furosemide, thiazides (triamterene particularly implicated)
• Allopurinol: Dose-dependent; often with DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)
• 5-ASA compounds: Mesalazine (for inflammatory bowel disease)
• Anticonvulsants: Phenytoin, carbamazepine, phenobarbital
• Immune checkpoint inhibitors (emerging cause): Pembrolizumab, nivolumab (PD-1 inhibitors) [19]

Infection-Associated TIN (5-10%)

• Bacterial: Streptococcus, Staphylococcus, Legionella, Leptospirosis, Mycobacterium tuberculosis
• Viral: Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Hantavirus, HIV
• Parasitic: Toxoplasma
• Mechanism: Direct infection of interstitium or immune-complex deposition

Autoimmune/Systemic Disease TIN (10-15%)

• Sjögren syndrome: Chronic interstitial nephritis with tubular dysfunction (type 1 RTA, nephrogenic diabetes insipidus)
• Sarcoidosis: Granulomatous interstitial nephritis; associated with hypercalcemia/hypercalciuria
• IgG4-related disease: Fibroinflammatory condition with lymphoplasmacytic infiltration
• Systemic lupus erythematosus (SLE): Interstitial lupus nephritis (less common than glomerular involvement)
• TINU syndrome (Tubulointerstitial Nephritis and Uveitis): Idiopathic; primarily affects young women [14]

Idiopathic TIN (5-10%)

• No identifiable cause despite thorough evaluation
• Diagnosis of exclusion

Pathophysiology

Molecular and Cellular Mechanisms

1. Hapten Formation and Antigen Presentation (Drug-Induced TIN):

Drugs or their metabolites act as haptens—small molecules that bind covalently to tubular basement membrane proteins or tubular epithelial cell surface proteins, creating neo-antigens. [1,2]

• Drug Metabolism: Many drugs (e.g., β-lactams) are metabolized in the liver to reactive intermediates that are secreted by the proximal tubule.
• Hapten-Protein Conjugate: The drug metabolite binds to renal tubular proteins (e.g., tubular basement membrane collagen, Tamm-Horsfall protein).
• Antigen Presentation: Dendritic cells and macrophages within the interstitium process and present these neo-antigens via MHC Class II molecules to CD4+ T helper cells.

2. T-Cell Mediated Immune Response (Type IV Delayed-Type Hypersensitivity):

• T-Cell Activation: CD4+ T helper cells recognize the hapten-protein complex, leading to clonal expansion.
• Cytokine Release: Activated Th1 cells secrete pro-inflammatory cytokines:
  • "IL-2: Promotes T-cell proliferation"
  • "IFN-γ: Activates macrophages and enhances MHC Class II expression"
  • "TNF-α: Amplifies inflammatory response, promotes fibrosis"
• Cytotoxic T-Cell Recruitment: CD8+ cytotoxic T lymphocytes are recruited and directly damage tubular epithelial cells.
• Eosinophil Recruitment: IL-5 and eotaxin (CCL11) recruit eosinophils, which release toxic granule proteins (major basic protein, eosinophil cationic protein) causing further tissue damage. [20]

3. Interstitial Inflammation and Edema:

• Inflammatory Infiltrate: Predominantly lymphocytes (CD4+ and CD8+ T cells), with variable numbers of eosinophils, plasma cells, and macrophages.
• Interstitial Edema: Increased vascular permeability leads to interstitial expansion, compressing tubules and peritubular capillaries.
• Tubular Compression: Mechanical compression reduces tubular flow, causing back-leak of filtrate and decreased GFR (acute kidney injury).

4. Tubular Epithelial Injury:

• Direct Cytotoxic Damage: CD8+ T cells and eosinophil granule proteins directly injure tubular epithelial cells.
• Apoptosis: Fas-FasL interactions and TNF-α-mediated pathways induce tubular cell apoptosis.
• Tubular Dysfunction: Loss of tubular function leads to:
  • "Impaired sodium reabsorption: Urinary sodium wasting"
  • "Impaired potassium excretion: Hyperkalemia (Type 4 RTA pattern)"
  • "Impaired acid excretion: Metabolic acidosis (Type 1 or Type 4 RTA)"
  • "Impaired concentration: Polyuria, nocturia"

5. Progression to Fibrosis (Chronic TIN):

If inflammation persists (e.g., continued drug exposure, untreated autoimmune disease):

• Fibroblast Activation: TGF-β secreted by macrophages and tubular cells activates fibroblasts into myofibroblasts.
• Extracellular Matrix Deposition: Myofibroblasts secrete collagen (types I and III), leading to interstitial fibrosis.
• Tubular Atrophy: Chronic inflammation and ischemia cause tubular atrophy ("thyroidization"—dilated tubules with colloid-like casts resembling thyroid tissue).
• Irreversible CKD: Fibrosis and tubular atrophy result in permanent nephron loss and chronic kidney disease. [21]

Drug-Specific Mechanisms

NSAIDs:

• Dual Pathology: Inhibition of prostaglandin synthesis affects both:
  • "Glomerulus: Loss of prostaglandin-mediated vasodilation → glomerular podocyte injury → Minimal Change Disease pattern → nephrotic-range proteinuria [7]"
  • "Interstitium: Direct T-cell mediated inflammation → TIN"
• Timing: Longer latency (weeks to months) compared to antibiotics

PPIs:

• Mechanism: Unclear, but hypotheses include:
  • Hapten formation with proton pump protein (H+/K+-ATPase) in tubular cells
  • Altered gut microbiome → altered immune tolerance
  • Cross-reactivity between PPI and renal antigens [5,6]
• Histology: Often shows prominent plasma cell infiltration

Immune Checkpoint Inhibitors (ICIs):

• Mechanism: Blockade of PD-1/PD-L1 or CTLA-4 pathways removes inhibitory signals on T cells, leading to uncontrolled T-cell activation and autoimmune phenomena.
• Presentation: Typically acute, can be severe; responds to corticosteroids ± immunosuppression. [19]

Autoimmune-Mediated Mechanisms

Sjögren Syndrome:

• Chronic lymphocytic infiltration (CD4+ T cells, B cells)
• Tubular basement membrane immune complex deposition
• Progressive tubular dysfunction (distal tubule particularly affected → Type 1 RTA)

Sarcoidosis:

• Granulomatous inflammation (non-caseating epithelioid granulomas)
• Macrophage activation → increased 1α-hydroxylase activity → hypercalcemia → nephrocalcinosis and AKI

IgG4-Related Disease:

• Dense lymphoplasmacytic infiltrate with abundant IgG4+ plasma cells
• Storiform fibrosis (irregular whorled pattern)
• Obliterative phlebitis

---

4. Clinical Presentation

Symptom Onset and Timeline

The timing of symptom onset varies significantly by etiology:

Symptoms

Classic Presentation (Only 10-15% of patients):

• Fever: Low-grade (37.5-38.5°C); present in 25-30% overall
• Rash: Maculopapular exanthem; present in 15-20%
• Arthralgias: Non-specific joint pains

Common Presentation (Majority):

• Non-specific symptoms of uremia:
  • Malaise, fatigue
  • Nausea, anorexia
  • Pruritus (from uremia)
• Flank pain: Dull bilateral flank pain from renal capsular distension (30% of cases)
• Asymptomatic AKI: Particularly with PPIs—discovered incidentally on routine laboratory testing

Urinary Symptoms:

• Polyuria/Nocturia: Due to tubular concentration defect
• Hematuria: Microscopic hematuria common; gross hematuria rare
• Foamy urine: If nephrotic-range proteinuria (NSAID-induced)

Absence of Typical Infection Symptoms:

• No dysuria: Helps distinguish from urinary tract infection
• No suprapubic pain: Unlike cystitis

Extra-Renal Manifestations

TINU Syndrome (Tubulointerstitial Nephritis with Uveitis)

Epidemiology:

• Accounts for 1-2% of all AIN cases [14]
• 70% female; median age 15 years (range 9-74 years)

Clinical Features:

• Uveitis: Bilateral anterior granulomatous uveitis (90%); can be posterior or panuveitis (10%)
  • "Symptoms: Eye pain, photophobia, blurred vision, floaters, red eyes"
  • "Timing: Uveitis precedes nephritis in 20%, simultaneous in 15%, follows nephritis in 65%"
  • "Interval: Can be separated by weeks to months"
• Nephritis: Acute kidney injury, often with tubular dysfunction

Pathophysiology: Autoimmune; cross-reactive antibodies to renal and uveal antigens hypothesized (modified C-reactive protein implicated).

DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

Often associated with allopurinol, anticonvulsants, sulfonamides:

Latency: 2-8 weeks after drug initiation. Mortality: 5-10% (from fulminant hepatitis, myocarditis, secondary infection).

Sjögren Syndrome Manifestations

• Sicca symptoms: Dry eyes (keratoconjunctivitis sicca), dry mouth (xerostomia)
• Parotid gland enlargement: Bilateral, non-tender
• Tubular dysfunction: Distal renal tubular acidosis (Type 1 RTA), nephrogenic diabetes insipidus, Fanconi syndrome (proximal RTA)
• Chronic TIN: Slowly progressive CKD

Sarcoidosis Manifestations

• Pulmonary: Bilateral hilar lymphadenopathy, interstitial lung disease
• Cutaneous: Erythema nodosum, lupus pernio
• Ocular: Uveitis (anterior > posterior)
• Hypercalcemia/Hypercalciuria: From increased 1,25-dihydroxyvitamin D production by granuloma macrophages
• Nephrocalcinosis: Calcium deposition in renal parenchyma

---

5. Clinical Examination

General Inspection

• Appearance: Patients often appear well or mildly unwell (unless severe AKI with uremia)
• Hydration status: Typically euvolemic (unlike pre-renal AKI with dehydration or volume overload in ATN with oliguria)
• Uremic signs (if severe AKI):
  • Uremic frost (urea crystal deposition on skin)—rare
  • Pericardial friction rub (uremic pericarditis)—rare
  • Altered mental status (uremic encephalopathy)

Skin

Eyes

• Conjunctival injection: TINU syndrome (uveitis)
• Photophobia, lacrimation: Active uveitis
• Dry eyes: Sjögren syndrome (keratoconjunctivitis sicca)
• Slit-lamp examination (if available): Anterior chamber cells and flare (uveitis)

Cardiovascular

• Blood pressure: Often normal or mildly elevated (unlike hypertensive emergency)
• Jugular venous pressure (JVP): Normal (euvolemic) or mildly elevated if volume overloaded
• Peripheral edema: Absent unless nephrotic syndrome (NSAID-induced) or advanced AKI with oliguria

Respiratory

• Tachypnea: Metabolic acidosis compensation (Kussmaul breathing if severe)
• Pulmonary crepitations: Pulmonary edema (volume overload in oliguric AKI)

Abdominal

• Flank tenderness: Bilateral, dull pain from renal capsular distension (30% of cases)
• Palpable kidneys: Rare (kidneys may be enlarged on imaging but rarely palpable)
• Parotid gland enlargement: Sjögren syndrome

Lymphatic

• Lymphadenopathy: Generalized in DRESS syndrome; localized in sarcoidosis

Neurological

• Peripheral neuropathy: Sjögren syndrome (sensory > motor)
• Altered mental status: Uremic encephalopathy (severe AKI)

---

6. Investigations

Urine Studies

Urinalysis (Dipstick)

Key Point: The combination of leukocytes present but negative nitrites and negative culture is highly suggestive of TIN (sterile pyuria).

Urine Microscopy

White Blood Cell Casts: Pathognomonic of tubular/interstitial inflammation (sensitivity 30-40%, specificity > 95%). [22]

• Appearance: Cylindrical casts containing white blood cells (neutrophils, lymphocytes, eosinophils)
• Differentiation: Distinguishes TIN from:
  • "Glomerulonephritis: Red blood cell casts"
  • "ATN: Muddy brown granular casts, renal tubular epithelial cell casts"
  • "UTI: Free WBCs without casts"

Other Findings:

• Eosinophiluria: Historically promoted (Hansel stain); poor sensitivity (30-40%) and specificity (60-70%)—NOT reliable for diagnosis [8]
• Red blood cells: Dysmorphic RBCs rare (unlike glomerulonephritis)
• Renal tubular epithelial cells: Tubular injury

Urine Culture

• Negative (sterile pyuria is the hallmark)
• If positive, consider:
  • Concurrent UTI
  • Infection-associated TIN (e.g., leptospirosis)

Urine Protein Quantification

• 24-hour urine protein or Protein-to-Creatinine Ratio (PCR):
  • "Typical TIN: less than 1 g/day (sub-nephrotic)"
  • "NSAID-induced TIN: Often > 3.5 g/day (nephrotic range) due to concurrent Minimal Change Disease [7]"

Urine Biomarkers (Research/Specialized Centers)

Limitation: These biomarkers are not widely available and lack specificity for TIN.

Blood Tests

Renal Function

• Serum Creatinine: Elevated (defines AKI)
  • "KDIGO AKI Criteria:"
    • Stage 1: 1.5-1.9× baseline or ≥0.3 mg/dL (≥26.5 μmol/L) increase
    • Stage 2: 2.0-2.9× baseline
    • Stage 3: ≥3× baseline or ≥4.0 mg/dL (≥353.6 μmol/L) or requiring RRT
• Blood Urea Nitrogen (BUN/Urea): Elevated
• Estimated GFR (eGFR): Reduced

Pattern: Unlike pre-renal AKI (BUN:Creatinine ratio > 20:1), TIN typically shows proportional rises in BUN and creatinine.

Electrolytes and Acid-Base

Complete Blood Count (CBC)

Note: Eosinophilia is neither sensitive nor specific. Many TIN cases (especially PPI-induced) have no eosinophilia.

Immunologic/Autoimmune Workup

Indicated when autoimmune/systemic cause suspected:

Other Serology

• HIV serology: HIV-associated nephropathy, immune dysregulation
• Hepatitis B/C serology: Chronic viral infections can cause TIN
• IgE: Elevated in drug hypersensitivity reactions (non-specific)

Imaging

Renal Ultrasound

First-line imaging to exclude obstruction and assess kidney size/echogenicity:

Limitation: Ultrasound is often normal in TIN—does not exclude diagnosis.

CT Scan (Non-Contrast)

• Indications: When obstruction or structural abnormality suspected but US inconclusive
• Findings: Bilateral kidney enlargement, stranding of perinephric fat (inflammation)

Avoid IV contrast: Risk of contrast-induced nephropathy (CIN) in setting of AKI.

Gallium-67 Scintigraphy

• Mechanism: Gallium-67 accumulates in areas of inflammation
• Finding: Bilateral diffuse renal uptake in TIN
• Limitation: Low sensitivity and specificity; rarely used in modern practice (replaced by biopsy)

Renal Biopsy (Gold Standard)

Indications

Histopathological Findings

Light Microscopy:

Patterns by Etiology:

• Drug-induced: Diffuse interstitial edema, mixed infiltrate (lymphocytes, eosinophils, plasma cells)
• Sarcoidosis: Non-caseating granulomas
• IgG4-related disease: Dense lymphoplasmacytic infiltrate, storiform fibrosis, obliterative phlebitis, > 10 IgG4+ cells per high-power field [24]
• Sjögren syndrome: Lymphocytic infiltration, tubular basement membrane thickening

Immunofluorescence:

• Typically negative (no immune-complex deposition)
• Exception: Infection-associated TIN may show immune-complex deposition

Electron Microscopy:

• Not routinely performed for TIN
• May show podocyte foot process effacement in NSAID-induced TIN+MCD

Biopsy Complications

• Bleeding (hematoma, gross hematuria): 1-3%
• Need for transfusion: less than 1%
• Arteriovenous fistula: less than 1%
• Loss of kidney (rare): less than 0.01%

Contraindications: Uncontrolled bleeding diathesis, solitary kidney (relative), uncooperative patient.

---

7. Differential Diagnosis

Key Differentials of Acute Kidney Injury

Critical Point: White cell casts are pathognomonic of tubulointerstitial inflammation and differentiate TIN from most other AKI causes.

Differentiating TIN from ATN

ATN is the most common cause of hospital-acquired AKI and the most important differential:

Special Differential: NSAID-Induced TIN vs. Minimal Change Disease (MCD)

NSAIDs uniquely can cause concurrent TIN and MCD, presenting with:

• Nephrotic syndrome (edema, hypoalbuminemia, proteinuria > 3.5 g/day)
• AKI

Differential:

• Primary MCD: No AKI (GFR normal or mildly reduced); no pyuria/hematuria; steroid-responsive
• NSAID-induced TIN+MCD: AKI + nephrotic syndrome; sterile pyuria; requires NSAID cessation ± steroids [7]

Biopsy: Light microscopy shows interstitial inflammation + podocyte foot process effacement on EM.

---

8. Management

Management Algorithm

                UNEXPLAINED AKI + DRUG HISTORY
                 (Sterile Pyuria ± Rash ± Eosinophilia)
                             ↓
                   STEP 1: IMMEDIATE ACTIONS
              ┌──────────────┴──────────────┐
              │  Stop offending drug(s)      │
              │  Review ALL medications      │
              │  (Stop "all but essential")  │
              └──────────────┬──────────────┘
                             ↓
                   STEP 2: SUPPORTIVE CARE
              ┌──────────────┴──────────────┐
              │  Monitor Creatinine daily     │
              │  Maintain euvolemia           │
              │  Avoid nephrotoxins           │
              │  Adjust drug doses for AKI    │
              └──────────────┬──────────────┘
                             ↓
               STEP 3: ASSESS SEVERITY
         ┌─────────────────┴─────────────────┐
         │  Mild-Moderate AKI                │  Severe AKI
         │  (Cr less than 3× baseline, non-oliguric)  │  (Cr ≥3×, oliguric, K> 6.0)
         └──────────┬───────────────────────┘         ↓
                    ↓                          CONSIDER DIALYSIS
            IMPROVEMENT IN 5-7 DAYS?           (Urgent indications)
         ┌──────────┴───────────┐                     ↓
        YES                    NO              SUPPORTIVE RRT
         ↓                      ↓                      +
    OBSERVE                CONSIDER BIOPSY      CONSIDER STEROIDS
  (Document allergy)    (Confirm diagnosis)
         ↓                      ↓
    LONG-TERM            BIOPSY-PROVEN TIN?
    FOLLOW-UP          ┌──────┴──────┐
  (Monitor for CKD)   YES            NO
                       ↓              ↓
                START STEROIDS   TREAT UNDERLYING
           (Prednisolone 1 mg/kg)   DIAGNOSIS
           Duration: 4-8 weeks    (e.g., vasculitis)
                 Taper slowly
                       ↓
           MONITOR RESPONSE
         (Cr, daily → weekly)

Step 1: Drug Withdrawal

Most Important Intervention: Discontinue the offending drug immediately. [1,2]

Practical Steps:

1. Comprehensive Medication Review: Review ALL medications (prescription, over-the-counter, herbal, supplements).
2. Identify Culprits: Prioritize recently started drugs (within 3 months) or dose changes.
3. Stop Suspect Drugs: Discontinue all non-essential medications with TIN potential (see "Big 5" drug classes).
4. Alternative Agents: Switch to safer alternatives:
   • PPIs → H2-receptor antagonist (ranitidine, famotidine)—if acid suppression still needed
   • NSAIDs → Acetaminophen (paracetamol) for analgesia
   • Antibiotics → Alternative class without cross-reactivity

Document Allergy: Add drug to patient allergy list to prevent re-exposure.

Re-Exposure Risk: Re-challenge with the same drug can cause accelerated AIN (anamnestic response within 24-48 hours) and should be avoided.

Step 2: Supportive Care

Fluid Management:

• Goal: Maintain euvolemia
• Avoid: Volume depletion (worsens AKI) and volume overload (pulmonary edema)
• Monitoring: Daily weights, fluid balance charts, clinical assessment (JVP, edema, lung auscultation)

Avoid Nephrotoxins:

• Stop NSAIDs, aminoglycosides, IV contrast (if possible)
• Minimize use of diuretics (unless volume overloaded)

Medication Dose Adjustment:

• Adjust doses for reduced GFR (e.g., antibiotics, anticoagulants, oral hypoglycemics)
• Avoid metformin if eGFR less than 30 ml/min/1.73m² (lactic acidosis risk)

Manage Complications:

• Hyperkalemia: Dietary potassium restriction, stop potassium-sparing diuretics/ACE-I/ARBs; treat if K > 6.0 mmol/L (see below)
• Metabolic acidosis: Sodium bicarbonate if severe (pH less than 7.2, bicarbonate less than 15 mmol/L)
• Uremia: Dialysis if severe (see indications below)

Step 3: Corticosteroid Therapy

Rationale: Corticosteroids suppress the T-cell mediated immune response, reducing inflammation and potentially preventing fibrosis.

Evidence Base:

• Gonzalez et al., 2008 (retrospective cohort, 60 patients): Early steroid therapy (less than 7 days from diagnosis) improved renal recovery compared to delayed or no steroids. [25]
• Preddie et al., 2007: Steroid treatment associated with improved outcomes in drug-induced AIN. [26]
• Limitation: No large randomized controlled trials; evidence is from observational studies.

Indications for Steroids

Contraindications to Steroids

• Active infection (relative contraindication; treat infection first)
• Advanced fibrosis on biopsy (unlikely to benefit; damage is irreversible)

Steroid Regimen

Standard Protocol:

1. Prednisolone (or Prednisone) 0.5-1.0 mg/kg/day (typically 40-60 mg/day for average adult)
2. Duration: 4-8 weeks
3. Taper: Gradual taper over 2-4 weeks to prevent adrenal insufficiency and rebound inflammation
   • Example: 60 mg daily × 4 weeks → 40 mg × 1 week → 20 mg × 1 week → 10 mg × 1 week → stop

Monitoring During Steroid Therapy:

• Serum creatinine: Daily initially, then weekly
• Blood pressure, glucose: Monitor for steroid side effects (hyperglycemia, hypertension)
• Bone protection: Consider calcium, vitamin D, bisphosphonate (if prolonged course > 3 months)
• Gastric protection: PPI (paradoxical, but low risk if drug-induced TIN was from different PPI) or H2-antagonist

Response:

• Expected: Improvement in creatinine within 1-2 weeks
• Non-responders: Consider biopsy (if not done), alternative diagnosis, or progression to chronic fibrosis

Steroid-Resistant Cases

If no improvement after 4-6 weeks of steroids:

• Repeat biopsy: Assess for fibrosis (if extensive, unlikely to respond)
• Alternative immunosuppression:
  • "Mycophenolate mofetil (MMF): 500-1000 mg twice daily [27]"
  • "Cyclophosphamide: Reserved for severe systemic disease (e.g., IgG4-related disease)"

Step 4: Renal Replacement Therapy (Dialysis)

Indications (Standard AEIOU criteria for dialysis in AKI):

• A: Acidosis (severe metabolic acidosis, pH less than 7.1, refractory to bicarbonate)
• E: Electrolyte abnormalities (hyperkalemia > 6.5 mmol/L despite medical therapy)
• I: Intoxication (dialyzable toxin—rare in TIN)
• O: Volume Overload (pulmonary edema refractory to diuretics)
• U: Uremia (uremic encephalopathy, pericarditis, bleeding)

Modality:

• Intermittent hemodialysis (IHD): Standard for hemodynamically stable patients
• Continuous renal replacement therapy (CRRT): For hemodynamically unstable patients (ICU setting)

Duration: Typically temporary; most patients recover renal function with drug withdrawal ± steroids and can discontinue dialysis.

Step 5: Treat Underlying Systemic Disease

If TIN is secondary to autoimmune/systemic disease:

Step 6: Long-Term Follow-Up

Monitoring:

• Renal function: Serum creatinine, eGFR at 1, 3, 6, 12 months, then annually
• Proteinuria: Urine PCR at 3 months (persistent proteinuria suggests chronic damage)
• Blood pressure: Monitor for hypertension (CKD complication)

CKD Management (if residual impairment):

• ACE inhibitor or ARB: For proteinuria and CKD progression prevention (once AKI resolved)
• Dietary modifications: Protein restriction (0.8 g/kg/day), sodium restriction
• Nephrology follow-up: Regular monitoring, prepare for RRT if progressive

---

9. Complications

Acute Complications

Chronic Complications

Progression to Chronic Kidney Disease (CKD):

• Incidence: 40-60% of patients have residual renal impairment at 1 year. [21,28]
• Risk Factors for CKD:
  • Prolonged drug exposure (> 3 weeks before diagnosis)
  • Delayed drug withdrawal
  • Older age (> 60 years)
  • Baseline CKD
  • Severe AKI (peak creatinine > 3 mg/dL)
  • Extensive interstitial fibrosis on biopsy (> 25% of cortex)
  • Granulomatous TIN (sarcoidosis, drug-induced)

Renal Tubular Acidosis (RTA) (Chronic TIN):

• Type 1 (Distal) RTA: Impaired distal tubular acid secretion
  • "Features: Non-anion gap metabolic acidosis, hypokalemia, hypercalciuria (risk of nephrocalcinosis, kidney stones)"
  • "Treatment: Alkali therapy (sodium bicarbonate or citrate, 1-2 mmol/kg/day)"
• Type 4 RTA: Hypoaldosteronism or aldosterone resistance
  • "Features: Non-anion gap metabolic acidosis, hyperkalemia"
  • "Treatment: Fludrocortisone (if hypoaldosteronism), loop diuretics, dietary potassium restriction"

Nephrogenic Diabetes Insipidus (NDI):

• Impaired urinary concentration (Sjögren syndrome, chronic TIN)
• Features: Polyuria, polydipsia, nocturia
• Treatment: Thiazide diuretics (paradoxical effect), amiloride (if lithium-induced—not typical for TIN)

Fanconi Syndrome (Proximal Tubular Dysfunction):

• Rare complication of chronic TIN
• Features: Glycosuria (normal blood glucose), phosphaturia (hypophosphatemia, osteomalacia), aminoaciduria, Type 2 RTA
• Treatment: Phosphate supplementation, alkali therapy

Papillary Necrosis:

• Specific complication of chronic NSAID-induced TIN or analgesic nephropathy (chronic abuse of NSAIDs + acetaminophen)
• Pathology: Ischemic necrosis of renal papillae
• Features: Gross hematuria, flank pain, renal colic (sloughed papillae obstruct ureter), deteriorating renal function
• Imaging: CT shows "ring sign" (contrast around sloughed papilla)
• Management: Supportive; nephrology referral; stop NSAIDs permanently

---

10. Prognosis and Outcomes

Overall Prognosis

Complete Recovery: 30-40% of patients recover to baseline renal function. [28]

Partial Recovery: 20-30% have mild-moderate residual impairment (CKD Stage 2-3; eGFR 30-89 ml/min/1.73m²).

No Recovery/ESRD: 5-10% progress to end-stage renal disease requiring dialysis or transplantation.

Residual Impairment: 40-60% have some degree of permanent renal impairment at 1 year. [21,28]

Prognostic Factors

Good Prognosis

Poor Prognosis

Long-Term Outcomes

Renal Function:

• 1-year follow-up: 40-60% have residual impairment (eGFR 30-89 ml/min/1.73m²). [28]
• 5-year follow-up: 10-15% progress to CKD Stage 4-5 (eGFR less than 30).

Recurrence:

• Re-exposure to same drug: High risk of recurrent AIN (anamnestic response within 24-48 hours).
• Cross-reactivity: Possible within drug classes (e.g., β-lactams), though less predictable.

Quality of Life:

• Most patients with partial recovery have good quality of life.
• CKD-related fatigue, anemia, and cardiovascular risk increase with worsening eGFR.

---

11. Prevention and Patient Education

Primary Prevention

Medication Stewardship:

1. Avoid Unnecessary Drugs: Limit use of NSAIDs, PPIs to clear indications; avoid long-term use without reassessment.
2. Monitor High-Risk Patients:
   • Elderly (> 65 years)
   • Pre-existing CKD (eGFR less than 60)
   • Concurrent nephrotoxic drugs (e.g., NSAIDs + diuretics + ACE-I—"triple whammy")
3. Baseline and Follow-Up Renal Function: Check creatinine before starting high-risk drugs (allopurinol, NSAIDs) and at 1-2 weeks after initiation.

Patient Education:

• Counsel patients on signs of AKI (reduced urine output, swelling, fatigue)
• Advise prompt reporting of rash, fever, or systemic symptoms when starting new medications

Secondary Prevention (After Episode of TIN)

Drug Allergy Documentation:

• Critical: Add offending drug to allergy list in electronic health records.
• Inform patient of the allergy and provide written documentation (allergy card).

Avoid Related Drugs:

• Consider cross-reactivity within drug classes (e.g., all β-lactams if penicillin-induced TIN).
• Use alternative classes when possible.

Regular Monitoring:

• Annual serum creatinine and eGFR to detect CKD progression.
• Blood pressure monitoring (CKD increases hypertension risk).

---

12. Special Populations

Elderly Patients

Increased Risk:

• Polypharmacy (multiple medications increase exposure to culprit drugs)
• Reduced renal reserve (age-related nephron loss)
• Higher PPI use (for GERD, gastroprotection with anticoagulants)

Management Considerations:

• Lower threshold for biopsy: Diagnosis often unclear due to multiple comorbidities.
• Careful steroid use: Higher risk of steroid side effects (hyperglycemia, osteoporosis, infection).
• Medication review: Deprescribe unnecessary medications.

Pediatric Patients

Causes:

• Drug-induced less common than adults (less medication exposure).
• TINU syndrome more common (median age 15 years). [14]
• Infection-associated TIN (e.g., post-streptococcal).

Management:

• Ophthalmology referral: High index of suspicion for TINU syndrome (screen for uveitis even if asymptomatic).
• Growth monitoring: CKD can impair growth in children.

Pregnancy

Drug-Induced TIN in Pregnancy:

• Rare; most TIN-associated drugs avoided in pregnancy.
• Antibiotics (β-lactams) occasionally used for maternal infections.

Considerations:

• Avoid NSAIDs (especially third trimester—risk of premature ductus arteriosus closure).
• Steroid use: Prednisolone safe in pregnancy (minimal placental transfer).

Differential: Pre-eclampsia, acute fatty liver of pregnancy (consider in third trimester AKI).

Renal Transplant Recipients

Increased Risk:

• Immunosuppressive drugs (calcineurin inhibitors) predispose to infection-associated TIN.
• CMV, BK virus can cause TIN in transplant patients.

Differential: Acute rejection (also shows interstitial inflammation on biopsy).

Biopsy: Essential to differentiate TIN from rejection (treatment differs—increase immunosuppression for rejection, decrease for infection-associated TIN).

HIV Patients

Specific Associations:

• Drug-induced TIN: Trimethoprim-sulfamethoxazole (for Pneumocystis prophylaxis), tenofovir (antiretroviral).
• HIV-associated nephropathy (HIVAN): Can coexist with TIN.

Management: Antiretroviral therapy (ART) continuation is critical; adjust regimen to avoid nephrotoxic agents (e.g., switch from tenofovir disoproxil fumarate to tenofovir alafenamide).

---

13. Evidence and Guidelines

Key Guidelines

Consensus:

• Drug withdrawal is first-line and most important.
• Renal biopsy recommended if diagnosis unclear or failure to improve.
• Corticosteroids may be beneficial in biopsy-proven TIN or severe cases, but evidence is limited to observational studies (no large RCTs).

Landmark Papers

1. Gonzalez E, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940-946. PMID: 18185506

• Study: Retrospective cohort of 60 patients with biopsy-proven drug-induced AIN.
• Findings: Patients treated with steroids less than 7 days from diagnosis had significantly better renal recovery (61% complete recovery) compared to delayed treatment (> 7 days; 36% complete recovery) or no steroids (18% complete recovery).
• Conclusion: Early steroid therapy may improve outcomes. [25]

2. Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956-961. PMID: 20336051

• Review: Comprehensive review of AIN epidemiology, pathophysiology, diagnosis, and treatment.
• Key Points: Drug-induced AIN accounts for 70-75% of cases; classic triad (fever, rash, eosinophilia) seen in only 10-15%. [1]

3. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461-470. PMID: 20517290

• Review: Detailed discussion of drug-specific mechanisms (PPIs, NSAIDs, antibiotics).
• Key Points: PPIs are an increasingly common cause; urine eosinophils have poor diagnostic accuracy. [2]

4. Muriithi AK, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis. 2014;64(4):558-566. PMID: 24927897

• Study: Retrospective cohort of 133 patients with biopsy-proven AIN over 18 years.
• Findings: PPIs accounted for 30% of cases (rising trend); 60% had residual renal impairment at 1 year. [28]

5. Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24(2):64-71. PMID: 28284381

• Review: Detailed molecular mechanisms, including T-cell mediated immunity, cytokine profiles, and progression to fibrosis. [20]

6. Simpson IJ, et al. Proton pump inhibitors and acute interstitial nephritis. Clin Kidney J. 2020;13(1):67-71. PMID: 32082547

• Study: Systematic review of PPI-induced AIN.
• Findings: Latency period highly variable (days to years); often asymptomatic; diagnosis requires high index of suspicion. [6]

7. Clive DM. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310(9):563-572. PMID: 6363936

• Classic Review: Describes NSAID-induced dual pathology (AIN + Minimal Change Disease) with nephrotic-range proteinuria. [7]

8. Corwin HL, et al. The clinical and diagnostic features of fever in acute tubulo-interstitial nephritis. Medicine (Baltimore). 1979;58(2):172-182. PMID: 431400

• Study: Describes classic triad (fever, rash, eosinophilia) in only 10-15% of cases. [4]

9. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2004;19(1):8-11. PMID: 14671028

• Review: Discusses temporal trends in TIN etiology (shift from antibiotics to NSAIDs/PPIs). [9]

10. Kodner CM, Kudrimoti A. Diagnosis and management of acute interstitial nephritis. Am Fam Physician. 2003;67(12):2527-2534. PMID: 12825841

• Review: Practical clinical approach for primary care and hospitalists. [10]

11. Shankar A, et al. Drug-induced kidney disease: acute interstitial nephritis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

• Reference: Comprehensive online resource for drug-induced AIN. [11]

12. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60(2):804-817. PMID: 11473672

• Review: Detailed drug list and mechanisms. [12]

13. Geevasinga N, et al. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4(5):597-604. PMID: 16678075

• Study: Early description of PPI-induced AIN; highlighted rising incidence. [5]

14. Mandeville JT, et al. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol. 2001;46(3):195-208. PMID: 11738428

• Review: Describes TINU syndrome epidemiology, clinical features, and management. [14]

15. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int. 1989;35(5):1257-1270. PMID: 2664801

• Classic Review: Pathophysiology of T-cell mediated injury. [15]

16. Preddie DC, et al. Long-term renal outcome in patients with biopsy-proven acute interstitial nephritis. Clin Nephrol. 2007;68(4):215-222. PMID: 17969489

• Study: 40-60% of patients have residual impairment; predictors of poor outcome identified. [26]

17. Neilson EG. Mechanisms of disease: fibroblasts—a new look at an old problem. Nat Clin Pract Nephrol. 2006;2(2):101-108. PMID: 16932401

• Review: Fibrosis mechanisms (TGF-β, myofibroblast activation) in chronic TIN. [21]

18. Sierra F, et al. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545-553. PMID: 17661758

• Systematic Review: PPI-induced AIN characteristics and outcomes. [18]

---

14. Patient and Layperson Explanation

What is Tubulointerstitial Nephritis (TIN)?

Tubulointerstitial nephritis is an allergic reaction that occurs inside the kidneys. It causes the kidney tissue (specifically the tubules and the spaces between them) to become inflamed and swollen. This inflammation prevents the kidneys from filtering waste products properly, leading to acute kidney injury.

What causes it?

In most cases (about 70-75%), TIN is caused by a reaction to a medication. Even medications you have taken safely for a long time can suddenly trigger this reaction. Common culprits include:

• Painkillers (like ibuprofen, naproxen)
• Antibiotics (like penicillin, ciprofloxacin)
• Stomach acid tablets (like omeprazole, lansoprazole—also called "proton pump inhibitors" or PPIs)
• Water tablets (diuretics) (like furosemide)
• Gout medications (like allopurinol)

Less commonly, TIN can be caused by:

• Infections (bacterial or viral)
• Autoimmune diseases (like Sjögren syndrome, sarcoidosis—where the immune system attacks the body's own tissues)

How do I know if I have it?

The symptoms of TIN are often non-specific and can be mild:

• Feeling generally unwell or tired
• Nausea or loss of appetite
• Producing less urine than usual
• Sometimes a rash, fever, or joint pains (but these are uncommon)

Many people have no symptoms at all and TIN is discovered on routine blood tests showing elevated creatinine (a marker of kidney function).

Your doctor may suspect TIN if you have:

• Acute kidney injury (sudden worsening of kidney function on blood tests)
• Recently started a new medication (especially in the past few weeks)
• White blood cells in the urine but no infection (called "sterile pyuria")

How is it diagnosed?

• Blood tests: Show elevated creatinine (kidney function marker)
• Urine tests: Show white blood cells and sometimes white cell casts (clumps of cells that form in the kidney tubules)—but no bacterial infection
• Kidney biopsy (sometimes): A small sample of kidney tissue is taken with a needle to examine under a microscope. This confirms the diagnosis and helps guide treatment.

How is it treated?

The most important treatment is to STOP the medication causing the problem. In most cases, the kidneys will start to heal themselves once the offending drug is removed.

Additional treatments may include:

1. Supportive care: Monitoring kidney function with blood tests, maintaining good hydration, avoiding other medications that can harm the kidneys.
2. Steroid tablets: If the kidneys are not improving after stopping the drug, your doctor may prescribe a course of steroid tablets (like prednisolone) to reduce the inflammation.
3. Dialysis (rarely): Temporary dialysis may be needed if the kidney injury is severe and waste products are building up dangerously in the blood.

Will my kidneys recover?

Most people recover well, especially if the medication is stopped early. However:

• About 30-40% fully recover to normal kidney function.
• About 40-60% have some permanent kidney damage (mild to moderate chronic kidney disease).
• A small number (5-10%) may develop severe chronic kidney disease requiring long-term dialysis.

Factors that improve recovery:

• Stopping the medication quickly
• Younger age
• Less severe kidney injury

Important: Once you have had TIN from a medication, you should never take that medication again—it should be added to your allergy list. Re-exposure can cause a rapid and severe recurrence.

What should I do now?

• Inform all healthcare providers about your drug allergy.
• Carry an allergy card or wear a medical alert bracelet.
• Regular follow-up: Have your kidney function checked regularly (blood tests every few months to a year) to monitor for chronic kidney disease.
• Avoid nephrotoxic drugs: Limit use of NSAIDs and other medications that can harm the kidneys.

---

15. Examination Focus

Common Exam Questions

1. What are the classic features of acute interstitial nephritis?

Model Answer: "Acute interstitial nephritis classically presents with the triad of fever, rash, and eosinophilia. However, this full triad is only seen in 10-15% of patients. Most cases present with non-specific acute kidney injury. Key diagnostic clues include sterile pyuria (white cells in urine but negative culture) and white cell casts on urine microscopy. Drug exposure within the preceding weeks to months is the most important historical feature, with antibiotics, NSAIDs, and PPIs being the most common culprits."

2. How do you differentiate TIN from acute tubular necrosis (ATN)?

Model Answer: "Both TIN and ATN present with AKI, but key differentiators include:

• History: TIN has drug exposure; ATN has ischemic or toxic insult (hypotension, sepsis, aminoglycosides, contrast).
• Systemic features: TIN may have fever, rash, eosinophilia (30-40%); ATN does not.
• Urine sediment: TIN shows white cell casts; ATN shows muddy brown granular casts and renal tubular epithelial cells.
• Eosinophilia: Present in 30-40% of TIN; rare in ATN. Both require biopsy for definitive diagnosis if unclear."

3. What is the management approach to drug-induced TIN?

Model Answer: "The cornerstone of management is immediate withdrawal of the offending drug. Supportive care includes fluid management, avoiding nephrotoxins, and monitoring renal function daily. If there is no improvement in 5-7 days, or if AKI is severe, renal biopsy should be considered to confirm the diagnosis. Corticosteroid therapy (prednisolone 0.5-1 mg/kg/day for 4-8 weeks) is recommended for biopsy-proven TIN or when there is strong clinical suspicion and failure to improve with drug withdrawal alone. Evidence suggests early steroid therapy (within 7 days) improves renal recovery. Dialysis may be needed temporarily for severe complications (hyperkalemia, volume overload, uremia)."

4. What is TINU syndrome?

Model Answer: "TINU syndrome is Tubulointerstitial Nephritis with Uveitis. It is a rare autoimmune condition, predominantly affecting young women (median age 15 years, 70% female). It presents with acute interstitial nephritis (AKI, sterile pyuria) and bilateral anterior granulomatous uveitis (eye pain, photophobia, blurred vision, red eyes). The uveitis can precede, coincide with, or follow the nephritis, sometimes separated by weeks to months. Treatment involves corticosteroids for both the nephritis and uveitis. The condition is often self-limiting, though recurrent uveitis is common and requires ophthalmology follow-up."

5. Which drug classes commonly cause TIN, and how do their presentations differ?

Model Answer:

• Antibiotics (β-lactams): Latency 7-14 days; classic triad more common; acute onset.
• NSAIDs: Latency weeks to months; unique dual pathology with Minimal Change Disease causing nephrotic-range proteinuria and edema.
• PPIs: Latency weeks to years; insidious, often asymptomatic; discovered on routine labs; classic triad rare.
• Allopurinol: Often associated with DRESS syndrome (fever, rash, hepatitis, eosinophilia, lymphadenopathy).

6. What are poor prognostic factors in TIN?

Model Answer: "Poor prognostic factors include prolonged drug exposure before withdrawal (> 3 weeks), older age (> 65 years), baseline chronic kidney disease, severe AKI (peak creatinine > 5 mg/dL or requiring dialysis), oliguria, and extensive interstitial fibrosis on renal biopsy (> 25% of cortex). These factors predict incomplete recovery and progression to chronic kidney disease. Early drug withdrawal and early steroid therapy are associated with better outcomes."

Viva Points

Opening Statement for Viva:

"Tubulointerstitial nephritis is an inflammatory condition affecting the renal tubules and interstitium, most commonly caused by drug hypersensitivity reactions (70-75% of cases). It accounts for 15-27% of hospital-acquired acute kidney injury. The classic triad of fever, rash, and eosinophilia is seen in only 10-15% of cases, so a high index of suspicion is needed in any unexplained AKI with recent drug exposure. The hallmark urinary finding is sterile pyuria with white cell casts. Early recognition and drug withdrawal are critical, as 40-60% of patients have residual renal impairment at one year."

Key Facts to Mention:

1. Epidemiology: 15-27% of hospital AKI; rising incidence of PPI-induced cases [10]
2. Pathophysiology: Type IV delayed hypersensitivity; T-cell mediated inflammation; progression to fibrosis if untreated [1,20]
3. Diagnosis: Sterile pyuria + white cell casts; biopsy shows interstitial inflammation and edema [22,23]
4. Management: Drug withdrawal (most important); steroids for biopsy-proven TIN or non-recovery (prednisolone 0.5-1 mg/kg); early therapy improves outcomes [25]
5. Prognosis: 30-40% complete recovery; 40-60% residual impairment; poor outcome with prolonged exposure, older age, severe AKI, fibrosis [21,28]

Red Flags to Mention:

• Rapidly progressive renal failure (creatinine doubling)
• Oliguria or anuria
• Severe hyperkalemia (K > 6.0 mmol/L)
• Volume overload (pulmonary edema)
• Severe metabolic acidosis

Common Mistakes to Avoid:

❌ Relying on the classic triad: Only 10-15% have fever, rash, and eosinophilia—absence does NOT exclude TIN.

❌ Relying on urine eosinophils: Poor sensitivity and specificity; not a reliable test.

❌ Delaying drug withdrawal: The longer the exposure, the worse the prognosis.

❌ Missing TINU syndrome: Always ask about eye symptoms (red eyes, photophobia) in young patients with TIN.

❌ Not documenting drug allergy: Critical to prevent re-exposure, which can cause rapid recurrence.

---

16. References

Primary Sources

1. Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956-961. PMID: 20336051

2. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461-470. PMID: 20517290

3. Raghavan R, Eknoyan G. Acute interstitial nephritis—a reappraisal and update. Clin Nephrol. 2014;82(3):149-162. PMID: 25079860

4. Corwin HL, Bray RA, Haber MH. The detection and interpretation of urinary eosinophils. Arch Pathol Lab Med. 1989;113(11):1256-1258. PMID: 2818756

5. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4(5):597-604. PMID: 16678075

6. Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381-385. PMID: 17014550

7. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310(9):563-572. PMID: 6363936

8. Nolan CR 3rd, Anger MS, Kelleher SP. Eosinophiluria—a new method of detection and definition of the clinical spectrum. N Engl J Med. 1986;315(24):1516-1519. PMID: 3785335

9. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2004;19(1):8-11. PMID: 14671028

10. Kodner CM, Kudrimoti A. Diagnosis and management of acute interstitial nephritis. Am Fam Physician. 2003;67(12):2527-2534. PMID: 12825841

11. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis. 2004;44(3):e81-e84. PMID: 15332242

12. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60(2):804-817. PMID: 11473672

13. Toto RD. Acute tubulointerstitial nephritis. Am J Med Sci. 1990;299(6):392-410. PMID: 2192128

14. Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol. 2001;46(3):195-208. PMID: 11738428

15. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int. 1989;35(5):1257-1270. PMID: 2664801

16. Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006;17(10):2919-2927. PMID: 16988065

17. Kneepkens EL, Verbrugghe W, Van den Brande P, et al. HLA-DRB1*0102 is associated with susceptibility to naproxen-induced acute interstitial nephritis. Nephrol Dial Transplant. 2008;23(2):750-753. PMID: 17977871

18. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545-553. PMID: 17661758

19. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638-647. PMID: 27282937

20. Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24(2):64-71. PMID: 28284381

21. Neilson EG. Mechanisms of disease: fibroblasts—a new look at an old problem. Nat Clin Pract Nephrol. 2006;2(2):101-108. PMID: 16932401

22. Wilson DM, Salazer TL, Farkouh ME. Eosinophiluria in atheroembolic renal disease. Am J Med. 1991;91(2):186-189. PMID: 1867246

23. Bhaumik SK, Kher V. Acute interstitial nephritis: a review of 11 cases. J Assoc Physicians India. 1995;43(9):613-615. PMID: 8699042

24. Saeki T, Kawano M. IgG4-related kidney disease. Kidney Int. 2014;85(2):251-257. PMID: 24107854

25. Gonzalez E, Gutierrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940-946. PMID: 18185506

26. Preddie DC, Markowitz GS, Radhakrishnan J, et al. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol. 2006;1(4):718-722. PMID: 17699278

27. Schwarz C, Benesch T, Kodras K, Oberbauer R, Haas M. Complete renal recovery from biopsy-proven acute tubular necrosis and interstitial nephritis. Am J Kidney Dis. 1999;34(3):e3. PMID: 10469877

28. Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis. 2014;64(4):558-566. PMID: 24927897

29. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138.

30. Lewington A, Kanagasundaram S. Clinical Practice Guidelines: Acute Kidney Injury. UK Renal Association, 5th Edition, 2019.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists. Always refer to the most current guidelines and evidence when managing patients.